A detailed history of F transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, F holds 42,463 shares of VRTX stock, worth $21.3 Million. This represents 0.7% of its overall portfolio holdings.

Number of Shares
42,463
Previous 47,194 10.02%
Holding current value
$21.3 Million
Previous $22.1 Million 10.72%
% of portfolio
0.7%
Previous 0.8%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

SELL
$460.0 - $505.78 $2.18 Million - $2.39 Million
-4,731 Reduced 10.02%
42,463 $19.7 Million
Q2 2024

Jul 29, 2024

BUY
$392.81 - $485.53 $16.9 Million - $20.9 Million
43,093 Added 1050.79%
47,194 $22.1 Million
Q1 2024

Apr 23, 2024

SELL
$407.69 - $446.08 $11,415 - $12,490
-28 Reduced 0.68%
4,101 $1.71 Million
Q4 2023

Feb 01, 2024

BUY
$343.0 - $410.68 $1.42 Million - $1.7 Million
4,129 New
4,129 $1.68 Million
Q2 2022

Jul 20, 2022

SELL
$234.96 - $292.55 $2.37 Million - $2.95 Million
-10,076 Closed
0 $0
Q1 2022

Apr 22, 2022

SELL
$221.42 - $260.97 $1,992 - $2,348
-9 Reduced 0.09%
10,076 $2.63 Million
Q4 2021

Feb 04, 2022

BUY
$177.01 - $223.45 $1.79 Million - $2.25 Million
10,085 New
10,085 $2.21 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track F Portfolio

Follow F and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of F, based on Form 13F filings with the SEC.

News

Stay updated on F with notifications on news.